Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

References

• Koro CE Bowlin SJ Bourgeois N Fedder DO Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report Diabetes Care 2004 27 1 17 20 14693960
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes 1988 37 6 667 687 3289989
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Kendall DM Cuddihy RM Bergenstal RM Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use Eur J Intern Med 2009 20 Suppl 2 S329 S339 19580952
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Bailey CJ Kendall DM Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications Am J Med 2010 123 4 374.e379 e374.e318 20362759
   PubMed Web of Science ®Google Scholar
• Perley MJ Kipnis DM Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects J Clin Invest 1967 46 12 1954 1962 6074000
   PubMed Web of Science ®Google Scholar
• Elrick H Stimmler L Hlad CJJr Arai Y Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 1964 24 1076 1082 14228531
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Holst JJ The physiology of glucagon-like peptide 1 Physiol Rev 2007 87 4 1409 1439 17928588
   PubMed Web of Science ®Google Scholar
• Nauck MA Niedereichholz U Ettler R Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273 5 Pt 1 E981 E988 9374685
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M Larsen PJ Göke R Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats Am J Physiol 1996 271 4 Pt 2 R848 R856 8897973
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP Tschopp S Bock A Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J Clin Endocrinol Metab 2004 89 6 3055 3061 15181098
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP Hruz P Huber AR Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans Digestion 2006 73 2–3 142 150 16809911
   PubMed Web of Science ®Google Scholar
• Mudaliar S Henry RR Incretin therapies: effects beyond glycemic control Eur J Intern Med 2009 20 Suppl 2 S319 S328 19580951
   PubMed Web of Science ®Google Scholar
• Mudaliar S Henry RR Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function Am J Med 2010 123 Suppl 3 S19 S27 20206728
   PubMed Web of Science ®Google Scholar
• Byetta [package insert] San Diego, CA Amylin Pharmaceuticals, LLC 2011
   Google Scholar
• Victoza [package insert] Bagsvaerd, Denmark Novo Nordisk A/S 2011
   Google Scholar
• Bydureon [package insert] San Diego, CA Amylin Pharmaceuticals, LLC 2012
   Google Scholar
• Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 3 952 957 7883856
   PubMed Web of Science ®Google Scholar
• Januvia [package insert] Whitehouse Station, NJ Merck and Co, Inc 2007
   Google Scholar
• Onglyza [package insert] Princeton, NJ Bristol-Myers Squibb Company 2011
   Google Scholar
• Tradjenta [package insert] Ridgefield, CT Boehringer Ingelheim Pharmaceuticals, Inc 2011
   Google Scholar
• European Medicines Agency Vildagliptin: summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf Accessed Jun 2012
   Google Scholar
• Lovshin JA Drucker DJ Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 2009 5 5 262 269 19444259
   PubMed Web of Science ®Google Scholar
• Cersosimo E Gastaldelli A Cervera A Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects J Clin Endocrinol Metab 2011 96 6 1763 1770 21411546
   PubMed Web of Science ®Google Scholar
• Cervera A Wajcberg E Sriwijitkamol A Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab 2008 294 5 E846 E852 18334612
   PubMed Web of Science ®Google Scholar
• Kolterman OG Buse JB Fineman MS Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 2003 88 7 3082 3089 12843147
   PubMed Web of Science ®Google Scholar
• DeYoung MB MacConell L Sarin V Trautmann M Herbert P Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 2011 13 11 1145 1154 21751887
   PubMed Web of Science ®Google Scholar
• Anderson JM Shive MS Biodegradation and biocompatibility of PLA and PLGA microspheres Adv Drug Deliv Rev 1997 28 1 5 24 10837562
   PubMed Web of Science ®Google Scholar
• Lewis DH Controlled release of bioactive agents from lactide/glycolide polymers Chasin M Langer RS Biodegradable Polymers as Drug Delivery Systems New York Marcel Dekker 1990 1 41
   Google Scholar
• Vivitrol [package insert] Waltham, MA Alkermes, Inc 2010
   Google Scholar
• Fineman M Flanagan S Taylor K Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing Clin Pharmacokinet 2011 50 1 65 74 21142268
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C MacConell L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Blevins T Pullman J Malloy J DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 5 1301 1310 21307137
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 2013 381 9861 117 124 23141817
   PubMed Web of Science ®Google Scholar
• Wysham C Bergenstal R Malloy J DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide Diabet Med 2011 28 6 705 714 21434995
   PubMed Web of Science ®Google Scholar
• MacConell L Brown C Gurney K Han J Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials Diabetes Metab Syndr Obes 2012 5 29 41 22375098
   PubMedGoogle Scholar
• Fineman MS Shen LZ Taylor K Kim DD Baron AD Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diabetes Metab Res Rev 2004 20 5 411 417 15343588
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals Exenatide tQT study showed no prolongation of QT interval [press release] San Diego Amylin Pharmaceuticals 7 7 2011 Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1583328 Accessed May 2012
   Google Scholar
• Sager P Darpö B Han J Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes Diabetes 2011 60 A294
   Web of Science ®Google Scholar
• Linnebjerg H Seger M Kothare PA Hunt T Wolka AM Mitchell MI A thorough QT study to evaluate the effects of singledose exenatide 10 mcg on cardiac repolarization in healthy subjects Int J Clin Pharmacol Ther 2011 49 10 594 604 21961484
   PubMed Web of Science ®Google Scholar
• Buse JB Drucker DJ Taylor KL DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 2010 33 6 1255 1261 20215461
   PubMed Web of Science ®Google Scholar
• Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 1 150 156 21334333
   PubMed Web of Science ®Google Scholar
• Drucker DJ Sherman SI Bergenstal RM Buse JB The safety of incretin-based therapies – review of the scientific evidence J Clin Endocrinol Metab 2011 96 7 2027 2031 21734003
   PubMed Web of Science ®Google Scholar
• Dore DD Seeger JD Arnold Chan K Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 2009 25 4 1019 1027 19278373
   PubMed Web of Science ®Google Scholar
• Giovannucci E Harlan DM Archer MC Diabetes and cancer: a consensus report Diabetes Care 2010 33 7 1674 1685 20587728
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L Madsen LW Andersen S Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486 20203154
   PubMed Web of Science ®Google Scholar
• Hegedus L Moses AC Zdravkovic M Le Thi T Daniels GH GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J Clin Endocrinol Metab 2011 96 3 853 860 21209033
   PubMed Web of Science ®Google Scholar
• MacConell L Malloy J Huang W Cirincione B Shen L Porter L Safety and efficacy of once-monthly exenatide over 20 weeks in patients with type 2 diabetes Diabetologia 2011 54 S38
   Google Scholar
• Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus Am J Med 2005 118 Suppl 5A 27S 34S 15850551
   PubMed Web of Science ®Google Scholar
• Saini SD Schoenfeld P Kaulback K Dubinsky MC Effect of medication dosing frequency on adherence in chronic diseases Am J Manag Care 2009 15 6 e22 e33 19514806
   PubMed Web of Science ®Google Scholar
• Luskey L Rosenstock J Alessi T Henry RR Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS® device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes Diabetologia 2011 54 Suppl 1 S39
   Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Lorenzi G Schreiner B Osther J Boardman M Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device Clin Diabetes 2010 28 4 157 162
   Google Scholar
• Taylor K Kim D Nielsen LL Aisporna M Baron AD Fineman MS Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes Horm Metab Res 2005 37 10 627 632 16278786
   PubMed Web of Science ®Google Scholar